Audeara FY25 Trading Update

• Record revenue delivered in first 11 months of FY25, up 14% on FY24
• Growth underpinned by flagship launch of Clinico Sound Earbuds CS1 in Taiwan and strategic partnerships
• FY25 Australia wholesale revenue up 17% YTD on full FY24

Audeara Limited (ASX: AUA), a global hearing health leader specialised in innovative listening solutions, has provided a trading update for the first 11 months of financial year 2025 (FY25). The company's unaudited revenue from July 2024 to May 2025 exceeded $3.64 million, a 14% increase on the full FY24 total revenue of $3.185 million and a 25% uplift on total FY23 revenue of $2.9 million. This growth was underpinned by the flagship launch of the co-branded Audeara Buds, the Clinico Sound Earbuds CS1, in the Taiwan market, as well as a follow-up $0.917 million order from global music instrument manufacturer Avedis Zildjian. The company also achieved ongoing growth through Australian wholesale channels, with revenue between July 2024 and May 2025 up 16% on the previous corresponding period of $1.67 million. Audeara expects additional growth to materialise in the coming weeks based on strong June 2025 trading, which will include additional sales through Australian wholesale groups, retail sales and channels, and key resellers. Further sales growth for FY26 is also earmarked through ongoing collaborations with international counterparties and the company's AUA Technology division.

Audeara Limited (ASX: AUA) reported unaudited revenue from July 2024 to May 2025 exceeding $3.64 million, a 14% increase on the full FY24 total revenue of $3.185 million.

Audeara Limited (ASX: AUA) expects additional growth to materialise in the coming weeks based on strong June 2025 trading, which will include additional sales through Australian wholesale groups, retail sales and channels, and key resellers. Further sales growth for FY26 is also earmarked through ongoing collaborations with international counterparties and the company's AUA Technology division.